According to Palatin Technologies's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.25144. At the end of 2023 the company had a P/S ratio of 7.70.
Year | P/S ratio | Change |
---|---|---|
2023 | 7.70 | -16.22% |
2022 | 9.19 | -94.21% |
2021 | 159 | |
2020 | N/A | -100% |
2019 | 2.97 | -38.88% |
2018 | 4.86 | 144.49% |
2017 | 1.99 | |
2016 | N/A | |
2015 | N/A | -100% |
2014 | 2.34 | |
2013 | N/A | -100% |
2012 | 515 | 838.95% |
2011 | 54.8 | 1439.31% |
2010 | 3.56 | 103.7% |
2009 | 1.75 | -16.33% |
2008 | 2.09 | 89.45% |
2007 | 1.10 | -85.8% |
2006 | 7.77 | -25.86% |
2005 | 10.5 | -30.77% |
2004 | 15.1 | -66.18% |
2003 | 44.7 | -15.9% |
2002 | 53.2 | -69.07% |
2001 | 172 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.10 | -3.61% | ๐บ๐ธ USA |
AstraZeneca AZN | 4.59 | 7.85% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | 7.27 | 71.06% | ๐บ๐ธ USA |
MediciNova MNOV | 71.1 | 1,572.77% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | 9.86 | 131.83% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | N/A | N/A | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | 2.99 | -29.63% | ๐บ๐ธ USA |
GlycoMimetics
GLYC | N/A | N/A | ๐บ๐ธ USA |
Ardelyx ARDX | 13.6 | 221.03% | ๐บ๐ธ USA |